RPG Life Sciences opened lower at ₹2,848.00, compared with its previous close of ₹2,863.50. During today's session, the stock has traded between ₹2,761.10 and ₹2,848.00, with an average traded price of ₹2,792.87. It is currently showing a downward intraday trend.
An investment of ₹10,000 made 5 years ago in RPG Life Sciences is now worth
₹ 41,417.00
giving a profit of
₹ 31,417.00 (314.17%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
-56.90 (-1.99%)
Day High
₹2,848.00
Day Low
₹2,761.10
Day Open
₹2,848.00
Prev Close
₹2,863.50
Volume
17,304
Value Traded
₹4.83 Cr
1W Return
-3.10%
1M Return
4.00%
3M Return
-1.76%
6M Return
49.21%
1Y Return
21.08%
Market Cap (₹ Cr.)
4,642
PE Ratio
39.50
PB Ratio
7.81
Dividend Yield
0.84%
ROE
19.03%
ROCE
24.52%
Book Value (₹)
366.01
Face Value (₹)
8.00
EPS (TTM)
18.60
Industry PE
-
Beta
-
Debt to Equity
-
1 Week
-3.10%
6 Week
-
1 Month
4.00%
3 Month
-1.76%
9 Month
21.11%
Clarus Trust lifts RPG Life Sciences holding to 7.04%
Clarus Trust increased its stake in RPG Life Sciences by 0.23% via open market purchase. Total holding rose from 6.81% to 7.04% following the acquisition of 37,463 shares. Transaction completed on September 25, 2026, triggering Reg 29(2) SAST disclosure. Acquirer is not part of the promoter group; managed by ChrysCapital Associates LLP.
15 days agoRPG Active Pharma approves amalgamation of Actis Generics
RPG Active Pharma approved amalgamation of wholly owned subsidiary Actis Generics on September 25, 2026. Merger aims to simplify structure, reduce costs, and improve operational efficiencies. No shares issued as consideration; Actis shares held by RPG Active Pharma will be cancelled. Combined net worth stands at ₹69.35 crore; Actis contributed ₹45.96 crore in FY26 revenue.
15 days agoRPG Life Sciences plans analyst meet on September 22 at 10 am
RPG Life Sciences to host investor meet on September 22, 2026. Session part of Anand Rathi G-200 Summit in Mumbai. Group and one-on-one sessions planned for market participants.
26 days agoRPG Life Sciences completes slump sale of APIs business to Raghava
RPG Life Sciences completes slump sale of APIs and intermediates business. Buyer is Raghava Life Sciences Private Limited. Transaction executed via subsidiary RPG Active Pharma Limited. Transfer effective from September 16, 2026.
27 days agoRPG Life Sciences eyes acquisitions to expand API portfolio in 12 months
RPG Life Sciences plans more acquisitions to expand its API portfolio over the next 12 months. The strategy reflects an inorganic growth approach for the company's active pharmaceutical ingredients business. The development was reported by a newspaper.
1mo agoRPG Life Sciences posts Sep 3 investor call details on website
RPG Life Sciences posted details from its Sep 3, 2026 investor call on its website. The virtual session featured MD Ashok Nair and CFO Amol Lone. Materials are available at the company's official investor relations page.
1mo ago| Stock | LTP | Change % | Market Cap (Cr.) | PE | 1Y Return |
|---|---|---|---|---|---|
| ₹1,770.70 | +0.61% | ₹4,24,850.24 | 34.83 | +5.97% | |
| ₹9,285.00 | -1.50% | ₹2,46,487.58 | 85.12 | +43.41% | |
| ₹4,642.90 | -0.84% | ₹1,76,600.99 | 82.55 | +31.42% | |
| ₹1,132.50 | -0.17% | ₹1,12,967.31 | 24.74 | +14.00% | |
| ₹2,059.40 | -0.47% | ₹1,11,271.90 | 102.63 | +134.89% | |
| ₹1,329.60 | +1.40% | ₹1,07,412.86 | 31.62 | -14.87% | |
| ₹1,240.00 | +0.86% | ₹1,03,500.36 | 32.26 | -1.93% | |
| ₹2,372.00 | -1.17% | ₹97,974.30 | 47.92 | -3.57% | |
| ₹1,684.60 | -1.31% | ₹96,928.16 | 26.40 | +49.04% | |
| ₹1,953.60 | +0.96% | ₹89,336.17 | 16.03 | -0.29% | |
| ₹2,265.30 | -0.78% | ₹63,932.35 | 35.82 | +16.81% | |
| ₹5,250.00 | +0.86% | ₹62,771.63 | 28.34 | -3.75% |
An investment of ₹10,000 made 5 years ago in RPG Life Sciences is now worth
₹ 41,417.00
giving a profit of
₹ 31,417.00 (314.17%)
Note: Past profits do not guarantee future returns.
